

Optimizing Diagnosis and Treatment of Congestive Heart Failure in Primary Health Settings

Frans H. Rutten¹, Clare J. Taylor², Judith R. Brouwer³, FD Richard Hobbs^{2*}

¹Julius Center for Health Sciences and Primary Care, UMC Utrecht, Universiteitsweg 100, 3584 CG, Utrecht, The Netherlands.

²Nuffield Department of Primary Care Health Sciences, Radcliffe Primary Care Building, Woodstock Rd, University of Oxford, OX2 6GG, United Kingdom.

³Medcon International, Adriaan Pauwlaan 29, 2101 AJ Heemstede, The Netherlands.

*E-mail ✉ richard.hobbs@phc.ox.ac.uk

Received: 17 December 2021; Revised: 19 February 2022; Accepted: 21 February 2022

ABSTRACT

One of the most common chronic cardiovascular conditions that contributes to hospitalization, morbidity, and death among all heart patients is heart failure. The chance of developing heart failure is about 20% higher during one's lifespan. Symptomatic forecasts typically lack specificity and are seldom able to distinguish heart failure from other illnesses. Due to its financial and medical strain on the healthcare system, this disease poses a dilemma. However, the treatment and presentation of a patient with heart failure are still up for debate. This study will focus on how crucial it is for primary care doctors to diagnose and treat patients with congestive heart failure. Eligible published English-language papers, articles, and clinical trials were collected and categorized for this evaluation. Among them was PubMed, an electronic research engine. Details on the diagnosis and treatment of congestive heart failure, including definitions and classifications, were covered in this study. The primary care physician's approach often focuses on traditional palliative medicines before the disease worsens, and aims to assess various reports about patients with heart failure during their follow-up appointments.

Keywords: Congestive heart failure, Diagnosis, Management, Prognosis, Primary health care

How to Cite This Article: Rutten FH, Taylor CJ, Brouwer JR, Hobbs FDR. Optimizing Diagnosis and Treatment of Congestive Heart Failure in Primary Health Settings. *Ann Pharm Pract Pharmacother*. 2022;2:1-5. <https://doi.org/10.51847/FV3G1GDG03>

Introduction

One of the primary chronic cardiovascular disorders that leads to morbidity, mortality, and hospitalization for all heart patients is heart failure. The overall chance of having heart failure is roughly 20% greater [1, 2]. Men are 33% more likely than women to suffer heart failure, according to other research that calculated the entire lifetime risk percentage by gender [3, 4]. However, the prevalence of congestive heart failure varies depending on the community under study. However, for those over 70, it is believed that between 1% and 2% of people have heart failure, and it may rise to over 10% [4, 5]. In addition, the prevalence of chronic cardiovascular disorders has significantly increased in the last several decades [6, 7].

Typically, congestive heart failure is the later phase of a variety of cardiac conditions. The financial and medical strain it places on the healthcare system makes it a difficult issue. Congestive heart failure's pathological and physiological conditions have been better understood during the last 20 to 30 years, and novel approaches to finding treatments have been established [4, 8].

Nonetheless, there are still questions on how to treat and offer a patient with heart failure. In this overview, we will emphasize how crucial it is for primary care physicians to diagnose and treat patients with congestive heart failure.

In patients with severe heart failure, low-frequency neuromuscular stimulation is a secure and productive rehabilitative technique that may assist with symptoms and enhance activities by partially reversing the aberrant reaction to exercise [9].

According to an investigation by Sinuraya *et al.* [10], the cost of CVD has increased in all Bandung primary healthcare facilities after national health insurance was put into place.

This study will focus on how crucial it is for primary care doctors to diagnose and treat patients with congestive heart failure.

Materials and Methods

This review was collected and classified from eligible published English written documents, articles, and clinical trials. This electronic research engine was included: PubMed. The keywords “Congestive” ‘Heart’ and ‘Failure’ including words used in Mesh (((‘Diagnosis’ [Mesh])), ((‘Prognosis’ [Mesh])), ((‘Management’ [Mesh])), ((‘Primary’ [Mesh])) were used in combinations. This review discussed the diagnosis and management of Congestive heart failure, and the details regarding this topic, including definitions and classifications, were included in this review.

Results and Discussion

Review

Diagnosis

Symptoms and signs in clinical presentation

Congestive heart failure development and prognosis evaluation are based on the American College of Cardiology’s American Heart Association (ACC) and the European Society of Cardiology’s (ESC) 2016 recommendations for identifying and managing acute and chronic heart failure [11]. Forecasts based on symptoms are typically nonspecific and seldom distinguish heart failure from other illnesses. On the other hand, early indicators of heart failure, including apical impulse dislocation and elevated jugular vein stress, can be more precisely identified (**Table 1**) [11-13].

Table 1. Symptoms and signs in heart failure presentation [11-13]

Symptoms	Signs
Conventional symptoms	More specific
Breathlessness	Jugular venous pressure elevation
Orthopnea	Hepatojugular reflux
Reduced exercise tolerance	Gallop heart rhythm
Paroxysmal nocturnal dyspnea	Lateral apical impulse displacement
Tiredness, fatigability, and more time for exercise recovery	
Swelling on the ankles	
Less conventional	Less specific
Wheezing	Weight gain
Bloated feeling	Sudden weight loss
Nocturnal coughing	Tissue wasting
Loss of appetite	Cardiac murmur
Confusion	Peripheral oedema (ankle, sacral, scrotal)
Depression	Pulmonary crepitations
Palpitations	Dullness to percussion and reduced air entry
Dizziness	Tachycardia
Syncope	Cheyne-stokes respiration
Bendopnea	Hepatomegaly
	Tachypnoea and irregular pulse
	Ascites
	Cold extremities
	Oliguria

Risk factors and prognosis

The result of heart failure is generally linked to several important dependent and independent risk variables. One of the main risk variables that influences how illnesses turn out is ethnicity. Asian heart failure patients are projected to have a greater chance of death than their European contemporaries [14–16]. Gender disparities frequently make a noteworthy impact on patients' quality of life. Based on several studies, males are 33% more likely than females to have heart failure throughout their entire lives [3, 4]. Other research, nevertheless, revealed that females are more likely than most males to suffer from congestive heart failure. Furthermore, compared to males, females are more likely to endure typical cardiac failure with intact ejection fraction [17, 18]. Female physiological characteristics are distinct from males and are thought to be a significant risk factor for the eventual occurrence of heart failure (**Table 2**) [19].

Table 2. Female distinct physical and physiological characteristics in contrast to males [19]

Physiological and anatomical features	Women compared to men
Mass in the left ventricle	Lower
Apoptosis and cell turnover	Lower
Blood pressure	Lower
Resting heart rate	Higher
Contractility	Greater
Catecholamine-mediated vasoconstriction	Less
Coronary vessel caliber	Smaller

Repeated hospitalization and unexpected hospitalization of heart failure patients are associated with death markers [16, 20, 21]. Comorbid conditions, both cardiovascular and non-cardiovascular, have an impact on preserving the prognostic pronouncements of the course of congestive heart failure. The diagnosis and treatment of heart failure are significantly impacted by these diseases. Patients with congestive heart failure frequently have diabetes, anemia, and metabolic iron shortage (**Table 3**), all of which are known to complicate the prognostic evaluation of heart failure.

Table 3. Effects of heart failure on iron shortage and anemia [22]

Anemia	Iron deficiency
Renal impairment	Iron absorption impairment.
Chronic inflammatory disorder	Malnutrition and iron intake reduction.
Dysfunction of the Bone Marrow	Blood loss from the Gastrointestinal area.
Hemodilution	Sequestration brought on by a compromised iron transition causes chronic inflammation.
Iron deficiency anemia	

Diabetes mellitus may not enhance the chance of survival, but it does play a big part in the etiology that raises the risk of mortality for heart failure patients. The length of time, other comorbidities, and harm to organs all affect this (**Table 4**) [22, 23]. Patients with heart failure who have type 2 diabetes have a higher chance of dying than those who do not have the disease [22, 24].

Table 4. Classes of cardiovascular risk in diabetic patients [22, 23]

Cardiovascular risk degree	Condition
Very high	- Diabetes and cardiovascular disease that already exists together with end-organ damage. - Over three years of cardiovascular risk - Having diabetes for almost 20 years
High	Over ten years of diabetes is linked to cardiovascular risks rather than organ damage.
Moderate	- Type 1 diabetes in individuals over 35 with no cardiovascular risks for ten years; - Type 2 diabetes in those over 50 with no cardiovascular risks for ten years.

Practical management of congestive heart failure in primary healthcare

Patients with congestive heart failure may exhibit a range of severe signs and symptoms during the condition's progression. The primary care physician's strategy seeks to evaluate various reports about heart failure patients through their follow-up appointments, and frequently worries about traditional palliative medications before the situation worsens. A referral ought to be made if palliative treatment proves to be ineffective [25]. A concise overview of the practical treatment of heart failure with maintained ejection fraction is provided in **Table 5** [26].

Table 5. Palliative care for heart failure patients whose ejection fraction remains stable [26]

The lowest diuretic dosage that is useful for monitoring volume overflow
Moderate dietary sodium restriction
Teaching patients about weight fluctuations and how to keep their ideal weight
comprehensive monitoring and treatment guidance, especially for recently admitted patients
Keeping an eye on comorbidities such as blood pressure and blood sugar
strict regulation of heart rate and preservation of sinus rhythm
Treat myocardial ischemia
Patients who exhibit extreme daytime drowsiness or suspected respiratory issues should have their sleep evaluated.
Follow up with moderate regular physical activity

Conclusion

The lifetime risk of developing heart failure is approximately 20% higher. Congestive heart failure is typically the later phase of a variety of cardiac conditions. Due to the financial and medical strain it places on the healthcare system, it is portrayed as a complicated issue. Variations in gender and ethnicity frequently had a stronger effect on patients' quality of life. The American College of Cardiology's American Heart Association (ACC) and the European Society of Cardiology's (ESC) 2016 recommendations for identifying and managing acute and chronic heart failure, nonetheless, are crucial for determining the course and prognostic evaluation of congestive heart failure. Congestive heart failure can present with a range of severe signs and symptoms that patients may encounter throughout practical treatment. The main care doctor's strategy frequently focuses on traditional palliative medicines before the illness worsens, and aims to evaluate various reports about patients with heart failure during their follow-up appointments. A referral ought to be made if palliative treatment proves to be ineffective.

Acknowledgments: None

Conflict of Interest: None

Financial Support: None

Ethics Statement: None

References

1. Metra M, Teerlink JR. Heart failure. *Lancet*. 2017;390(10106):1981-95.
2. Rachamin Y, Meier R, Rosemann T, Flammer AJ, Chmiel C. Heart failure epidemiology and treatment in primary care: a retrospective cross-sectional study. *ESC Heart Fail*. 2021;8(1):489-97.
3. Bleumink GS, Knetsch AM, Sturkenboom MC, Straus SM, Hofman A, Deckers JW, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure: The Rotterdam study. *Eur Heart J*. 2004;25(18):1614-9.
4. Kurmani S, Squire I. Acute heart failure: definition, classification and epidemiology. *Curr Heart Fail Rep*. 2017;14(5):385-92.
5. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. *Heart*. 2007;93(9):1137-46.
6. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. *Circulation*. 2016;134(6):441-50.

7. Kjeldsen SE, Naditch-Brule L, Perlini S, Zidek W, Farsang C. Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the global cardiometabolic risk profile in patients with hypertension disease survey. *J Hypertens*. 2008;26(10):2064-70.
8. Skrzypek A, Mostowik M, Szeliga M, Wilczyńska-Golonka M, Dębicka-Dąbrowska D, Nessler J. Chronic heart failure in the elderly: still a current medical problem. *Folia Med Cracov*. 2018;58(4):47-56.
9. Elmasry DM, Elnahas NG, Khorshid H, Rahmy AF. The effect of low frequency neuromuscular stimulation on sympathetic activity in advanced heart failure. *J Adv Pharm Educ Res*. 2019;9(4):29-35.
10. Sinuraya RK, Rianti A, Suwantika AA. Cost minimization of cardiovascular disease (CVD) drugs in primary healthcare centers in Bandung, Indonesia. *J Adv Pharm Educ Res*. 2021;10(1):63-9.
11. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail*. 2016;18(8):891-975.
12. Kelder JC, Cramer MJ, van Wijngaarden J, van Tooren R, Mosterd A, Moons KG, et al. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. *Circulation*. 2011;124(25):2865-73.
13. Boonman-de Winter LJ, Rutten FH, Cramer MJ, Landman MJ, Zuithoff NP, Liem AH, et al. Efficiently screening heart failure in patients with type 2 diabetes. *Eur J Heart Fail*. 2015;17(2):187-95.
14. Nagai T, Sundaram V, Shoaib A, Shiraishi Y, Kohsaka S, Rothnie KJ, et al. Validation of U.S. mortality prediction models for hospitalized heart failure in the United Kingdom and Japan. *Eur J Heart Fail*. 2018;20(8):1179-90.
15. Cooper LB, Yap J, Tay WT, Teng TK, MacDonald M, Anand IS, et al. Multi-ethnic comparisons of diabetes in heart failure with reduced ejection fraction: insights from the HF-ACTION trial and the ASIAN-HF registry. *Eur J Heart Fail*. 2018;20(9):1281-9.
16. Tomasoni D, Adamo M, Lombardi CM, Metra M. Highlights in heart failure. *ESC Heart Fail*. 2019;6(6):1105-27.
17. Scardovi AB, Petruzzini M, Rosano A, Lucia AR, De Maria R. Heart failure phenotype in women. *G Ital Cardiol (Rome)*. 2012;13(5 Suppl 1):6s-11s.
18. Sciomer S, Moscucci F, Salvioni E, Marchese G, Bussotti M, Corrà U, et al. Role of gender, age and BMI in prognosis of heart failure. *Eur J Prev Cardiol*. 2020;27(2_suppl):46-51.
19. Bozkurt B, Khalaf S. Heart failure in women. *Methodist Debaque Cardiovasc J*. 2017;13(4):216-23.
20. Solomon SD, Dobson J, Pocock S, Skali H, McMurray JJ, Granger CB, et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. *Circulation*. 2007;116(13):1482-7.
21. Chioncel O, Mebazaa A, Harjola VP, Coats AJ, Piepoli MF, Crespo-Leiro MG, et al. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC heart failure long-term registry. *Eur J Heart Fail*. 2017;19(10):1242-54.
22. Paolillo S, Scardovi AB, Campodonico J. Role of comorbidities in heart failure prognosis part I: Anaemia, iron deficiency, diabetes, atrial fibrillation. *Eur J Prev Cardiol*. 2020;27(2_suppl):27-34.
23. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *Eur Heart J*. 2020;41(2):255-323.
24. Rørth R, Jhund PS, Kristensen SL, Desai AS, Køber L, Rouleau JL, et al. The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. *Eur J Heart Fail*. 2019;21(1):40-9.
25. Kavalieratos D, Gelfman LP, Tycon LE, Riegel B, Bekelman DB, Ikejiani DZ, et al. Palliative care in heart failure: rationale, evidence, and future priorities. *J Am Coll Cardiol*. 2017;70(15):1919-30.
26. Upadhyay B, Kitzman DW. Heart failure with preserved ejection fraction: new approaches to diagnosis and management. *Clin Cardiol*. 2020;43(2):145-55.